Valanafusp Alfa
Mucopolysaccharidosis Type 1
ArmaGen, Incprotein_peptidePhase 1/2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Mucopolysaccharidosis Type 1 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Aldurazyme Genzyme, a Sanofi Company | Phase 4 | A |
Iduronidase, .Alpha.-L-(8-Histidine) (Human) University of California, San Francisco | Phase 4 | BBB |
Rhidu Genzyme, a Sanofi Company | Phase 3 | BB |
Cyclophosphamide Masonic Cancer Center, University of Minnesota | Phase 2 | B |
Busulfanum Masonic Cancer Center, University of Minnesota | Phase 2 | B |
View all 15 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →